WAY-262611

1123231-07-1

C20H22N4

DMSO : >= 42 mg/mL (131.90 mM)

Stem Cell/Wnt

WAY-262611 is a wingless beta-Catenin agonist that increases bone formation rate with an EC₅₀ of 0.63 uM in TCF-Luciferase assay. IC50 & Target: EC50: 0.63 uM (beta-Catenin)^[1] In Vitro: WAY-262611 has the most potent activity in the primary assay, low kinase inhibition potential, and high solubility^[1]. In Vivo: WAY-262611 has excellent pharmacokinetic properties and shows a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration. Calvariae from wt mice treated with WAY-262611 shows statistically increased BFR, while similarly treated KO animals are no different from control. This indicates that WAY-262611 is acting via the Wnt beta-catenin pathway and most likely through inhibition of Dkk-1^[1].